The researchers have demonstrated that genetic and pharmacological approaches can be used to lower levels of toxic metabolites in the nervous system and thereby alleviate several symptoms of neurodegeneration.
"Our research is focused on better understanding of the mechanisms that contribute to onset and progression of disease symptoms in neurodegenerative disorders," said Professor Flaviano Giorgini, from the University of Leicester in UK.
"These are diseases in which specific populations of nerve cells within the brain die, leading to severe problems in movement and cognitive deficits in patients," Giorgini said.
"Our hope is that by improving our knowledge of how these nerve cells become sick and die in the brain, we can help devise ways to interfere with these processes, and thereby either delay disease onset or prevent disease altogether," Giorgini said.
The research utilised the common laboratory fruit fly Drosophila melanogaster in order to explore the role of specific metabolites in the kynurenine pathway that cause loss of nerve cells in models of Alzheimer's, Parkinson's and Huntington's diseases.
In the past, the researchers have found that they can use genetic approaches to inhibit (or "mute") the activity of two critical enzymes in this pathway - TDO and KMO - which lowers levels of the toxic metabolites and reduces nerve cell loss in a fruit fly model of Huntington's disease.
In the current study they have uncovered how inhibiting these two enzymes improves "symptoms" in flies because of increased levels of a "protective" kynurenine pathway metabolite known as kynurenic acid which counteracts the effects of the toxic metabolites.
"For example, we find that if we inhibit either TDO or KMO in Huntington's flies we reduce loss of neurons. In Alzheimer's or Parkinson's flies we see extension of the shortened lifespan exhibited by these flies, and we also reverse the defects they have in movement," he said.
"We have even used a drug-like chemical to inhibit TDO and found that this also alleviates 'symptoms'," Giorgini added.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
